Effect of KB003 in Subjects With Asthma Inadequately Controlled by Corticosteroids

NCT01603277 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

160

Enrollment

INDUSTRY

Sponsor class

Conditions

Moderate-to-Severe Asthma

Interventions

BIOLOGICAL: Anti-GM-CSF Monoclonal Antibody 400mg
OTHER: Placebo

Sponsor

Humanigen, Inc.